Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Zhengye Biotechnology Holding Limited ZYBT

Healthcare  —  Drug Manufacturers Specialty & Generic
1.31 0.00 0.00% as of 25 Sep
Market cap
$40.1M
P/E
—
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Zhengye Biotechnology Holding Limited (ZYBT) Business Profile

Updated before January 2025

Company Overview

Zhengye Biotechnology Holding Limited (ZYBT) is a prominent player in the biotechnology sector, known for its innovative approach to sustainable solutions. Founded in 2005, ZYBT has its headquarters in Shenzhen, China. The company was established by Dr. Li Wei, a visionary in the field of biotechnology, with a mission to harness the power of science and technology to improve human health and environmental sustainability. Under the leadership of CEO Dr. Zhang Ming, ZYBT has grown into a global entity with a strong presence in Asia, Europe, and North America.

Core Business Segments

ZYBT operates through several core business segments, each focusing on different aspects of biotechnology:

1. Agricultural Biotechnology

This segment is dedicated to developing genetically modified crops that are resistant to pests and diseases, thereby increasing yield and reducing the need for chemical pesticides. Key products include:

  • ZYBT Corn: A genetically engineered corn variety that offers higher resistance to drought and pests.
  • ZYBT Rice: A high-yield rice variant that is fortified with essential vitamins.

2. Environmental Biotechnology

ZYBT is committed to environmental sustainability through its innovative solutions for waste management and pollution control. Products and services include:

  • BioWaste Solutions: A range of products designed to convert organic waste into biofuels.
  • EcoClean: Bioremediation services that use microorganisms to clean up contaminated environments.

3. Pharmaceutical Biotechnology

This segment focuses on the development of biopharmaceuticals for the treatment of chronic diseases. Key offerings include:

  • ZYBT Insulin: A biosimilar insulin product that is more affordable and accessible.
  • ZYBT Antibodies: Monoclonal antibodies for cancer treatment.

Business Model

ZYBT’s business model revolves around integrating cutting-edge biotechnology with practical applications. The company generates revenue through the sale of its products, licensing agreements, and strategic partnerships with other biotech firms. ZYBT also invests heavily in research and development to maintain its competitive edge and expand its product portfolio.

Strategic Direction

Looking ahead, ZYBT aims to expand its product offerings in the pharmaceutical sector, with a focus on personalized medicine. The company is also committed to sustainability, with goals to reduce its carbon footprint and promote eco-friendly practices across its operations. ZYBT plans to explore new product categories, such as plant-based proteins and bio-based materials.

Competitive Landscape

ZYBT faces competition from several major players in the biotechnology industry, including Monsanto (now part of Bayer), Syngenta, and Amgen. These companies compete with ZYBT across various sectors, particularly in agricultural and pharmaceutical biotechnology.

Risk Factors

ZYBT is exposed to several risks, including:

  • Market Dependence: Reliance on the success of its core products and services.
  • Supply Chain Disruptions: Potential disruptions in the supply of raw materials and distribution channels.
  • Regulatory Challenges: Navigating complex regulatory environments in different countries.

Recent Developments

Recently, ZYBT launched a new line of eco-friendly bioplastics, which has gained significant attention in the market. The company has also entered into a strategic partnership with a leading pharmaceutical firm to co-develop a new cancer treatment. Global developments, such as the COVID-19 pandemic, have highlighted the importance of biotechnology, providing ZYBT with new opportunities for growth.

Investment Considerations

Investors considering ZYBT should weigh the following:

  • Strengths: Strong R&D capabilities, diverse product portfolio, and commitment to sustainability.
  • Risks: Market volatility, regulatory hurdles, and competition from established players.

Conclusion

Zhengye Biotechnology Holding Limited stands as a leader in the biotechnology industry, with a robust portfolio of innovative products and a clear vision for the future. As the company continues to expand its global footprint and explore new markets, it is well-positioned for sustained growth and success.